About Emil Kakkis
Emil Kakkis is a founder and chairman at Amlogenyx.
Emil Kakkis reports to the SEC as a director, officer or major shareholder of 2 public companies: Ultragenyx Pharmaceutical (RARE) and Biomarin Pharmaceutical (BMRN).
Emil Kakkis first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Emil Kakkis in the role, so the role may have started earlier or lasted longer.
Amlogenyx Inc.
Founder and Chairman
2024 – 2026 · Novato, CA
Develops an investigational gene therapy for people with Alzheimer's disease.
UI
Ultragenyx Pharmaceutical Inc.
President & CEO, director
2014 – 2026 · Public company (RARE)
BI
Biomarin Pharmaceutical Inc.
Chief Medical Officer
2006 – 2009 · Public company (BMRN)
Key Colleagues at Startups
The people Emil Kakkis works with at each company, as listed on that company's latest Form D.
Amlogenyx Inc. · Form D, Jul 9, 2026
John Pinion
Chief Operations Officer
Craig Gordon
Director
Sukumar Nagendran
Director
TH
Ted Huizenga
Executive officer
KP
Karah Parschauer
Executive officer